Table 1.
Clinicopathologic characteristics in patients with stage III colorectal cancer according to RAS mutation (n = 304)
| Variable, n (%) | No RAS mutation | RAS mutation | P‐value |
|---|---|---|---|
| (n = 170) | (n = 134) | ||
| Gender | |||
| Male | 99 (58) | 69 (51) | 0.24 |
| Female | 71 (42) | 65 (49) | |
| Age, year | |||
| Median (range) | 61 (36–74) | 59 (32–75) | 0.28 |
| Primary tumor location | |||
| Colon | 92 (54) | 72 (54) | 0.94 |
| Rectum | 78 (46) | 62 (46) | |
| Histopathologic grade | |||
| Well differentiated | 37 (22) | 36 (27) | 0.22 |
| Moderately differentiated | 120 (71) | 90 (67) | |
| Poorly differentiated | 10 (6) | 3 (2) | |
| Mucinous | 3 (1) | 5 (4) | |
| T stage | |||
| T1–3 | 113 (66) | 86 (64) | 0.67 |
| T4 | 57 (34) | 48 (36) | |
| N stage | |||
| N1 | 135 (79) | 112 (84) | 0.52 |
| N2 | 26 (15) | 18 (13) | |
| N3 | 9 (6) | 4 (3) | |
| Tumor stage | |||
| IIIa | 135 (79) | 111 (83) | 0.45 |
| IIIb | 35 (21) | 23 (17) | |
| Treatment | |||
| Surgery alone | 82 (48) | 70 (52) | 0.48 |
| Adjuvant UFT | 88 (52) | 64 (48) | |
| MMR | |||
| pMMR | 156 (92) | 125 (93) | 0.63 |
| dMMR | 14 (8) | 9 (7) | |
dMMR, deficient DNA mismatch repair; MMR, mismatch repair; pMMR, proficient mismatch repair; UFT, tegafur–uracil.